Department of Urology, Erciyes University, Kayseri, Turkey.
Department of Internal Medicine, Kayseri City Hospital, Kayseri, Turkey.
Urol J. 2020 Aug 25;17(5):517-521. doi: 10.22037/uj.v16i7.6204.
The present study was designed to compare the efficacy of alfuzosin therapy as an alpha-blocker in metabolic syndrome (MetS) and non-MetS patients with moderate lower urinary tract symptoms (LUTS).
This prospective study included male patients with obstructive voiding and had a moderate LUTS according to International Prostate Symptom Score (IPSS). Patients were divided into two groups: MetS and Non-MetS. Following the measurement of uroflowmetric parameters (maximum flow rate [Qmax], post-void residual volume [PVR], urine volume) and the determination of IPSS scores, the patients were initiated on alfuzosin 10 mg once daily for a period of 12 weeks. At the end of the therapy, treatment outcomes were determined based on uroflowmetric parameters and IPSS scores.
301 patients were included in the study (MetS: 160, non-MetS: 141). Pre-treatment uroflowmetric measurements and IPSS scores were similar in both groups. After the therapy, the median Qmax level increased from 12.80 (10.62-14.82) ml/s to 14.55 (12.00-16.60) ml/s in the MetS group and from 12.60 (8.60-14.60) ml/s to 15.70 (13.20-17.20) ml/s in the non-MetS group (p<0.001 for both). Similar statistically significant changes were valid for PVR and IPSS. Post-treatment Qmax, PVR values and IPSS scores were higher in the non-MetS patients compared to MetS patients.
Although the non-MetS patients had greater benefit from the alfuzosin therapy compared to the MetS patients, alfuzosin is an effective alpha-blocker in the treatment of MetS patients with moderate LUTS. Based on these findings, it is tempting to consider that MetS might be a negative factor for benign prostate hyperplasia treatment.
本研究旨在比较阿夫唑嗪作为一种α受体阻滞剂在代谢综合征（MetS）和非代谢综合征（非 MetS）伴中度下尿路症状（LUTS）患者中的疗效。
这项前瞻性研究纳入了有梗阻性排尿症状且国际前列腺症状评分（IPSS）显示中度 LUTS 的男性患者。患者被分为两组：MetS 组和非 MetS 组。测量尿流动力学参数（最大尿流率[Qmax]、剩余尿量[PVR]、尿量）和 IPSS 评分后，所有患者均开始服用阿夫唑嗪 10mg，每日一次，疗程 12 周。治疗结束时，根据尿流动力学参数和 IPSS 评分评估治疗结果。
共有 301 例患者纳入研究（MetS 组 160 例，非 MetS 组 141 例）。两组患者治疗前的尿流动力学测量和 IPSS 评分相似。治疗后，MetS 组的中位 Qmax 水平从 12.80（10.62-14.82）ml/s 升高至 14.55（12.00-16.60）ml/s，非 MetS 组从 12.60（8.60-14.60）ml/s 升高至 15.70（13.20-17.20）ml/s（两组均 p<0.001）。PVR 和 IPSS 也有类似的统计学显著变化。非 MetS 组患者治疗后的 Qmax、PVR 值和 IPSS 评分均高于 MetS 组。
尽管非 MetS 患者从阿夫唑嗪治疗中获益更大，但阿夫唑嗪对伴中度 LUTS 的 MetS 患者仍是一种有效的α受体阻滞剂。基于这些发现，令人不禁联想到 MetS 可能是良性前列腺增生治疗的一个负面因素。
